| Adamis Pharmaceuticals Corporation (OTCBB: ADMP), today announced the technology which constitutes its compound APC-100 received a Notice of Allowance for its patent application in Canada. Broad claims to a patent entitled "Chroman-Derived Anti-Androgens for Treatment of Androgen-Mediated Disorders" have been allowed. These include claims for the use of APC-100 to treat prostate cancer and for the use of APC-100 to prevent the occurrence or recurrence of prostate cancer. Notice of Allowance...continued ADMP |
Thursday, November 3, 2011
Adamis Prostate Cancer Drug APC-100 Receives Allowance for Patent in Canada
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment